問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberD933GC00001
Active

2018-11-30 - 2025-12-31

Phase III

Not yet recruiting1

Recruiting8

ICD-10C22.0

Liver cell carcinoma

ICD-10C22

Malignant neoplasm of liver and intrahepatic bile ducts

ICD-9155.0

Malignant neoplasm of liver, primary

  • Trial Applicant

  • Sponsor

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/04/01

Investigators and Locations

Principal Investigator Ting-Tsung Chang Division of General Internal Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Not yet recruiting

Audit

None

Principal Investigator Chang-Fang Chiu Division of General Internal Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 紀廣明 Digestive System Department

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator San-Chi Chen Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Audit

None

Principal Investigator Chih-Hung Hsu Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Audit

None

Principal Investigator TENG-YU LEE Digestive System Department

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 林正耀 Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Chang-Fang Chiu 未分科

Co-Principal Investigator

Audit

None

Principal Investigator Shi-Ming Lin Digestive System Department
Linkou Chang Gung Medical Foundation

Taiwan National PI

林錫銘

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

5 Recruiting

Audit

None

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    72 participants

  • Global

    720 participants